⁃ \- Participant has documented diagnosis of MM and measurable disease, defined as any of the following:.

⁃ i) M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or.

⁃ ii) M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP).

⁃ iii) For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels \> 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio.

• Participants received 1 to 3 prior lines of antimyeloma therapy.

• Participants achieved minimal response \[MR\] or better to at least 1 prior antimyeloma therapy.